10-Q: STAAR Surgical Reports Strong Q2 Growth, Returns to Profitability

STAAR Surgical Company's Q2 2026 results show a significant increase in net sales and a return to net income, driven by strong performance in China and improved gross margins.

Summary

• STAAR Surgical Company reported a substantial increase in net sales for the second quarter of 2026, reaching $93.5 million, an 111.0% rise compared to $44.3 million in the prior year period.
• The company achieved a gross profit of $69.7 million, with a gross profit margin of 74.5%, an improvement from 74.0% in the prior year quarter.
• Net income for the quarter was $8.1 million, or $0.16 per diluted share, a significant turnaround from a net loss of $16.8 million, or $(0.34) per share, in the same period last year.
• Selling, general, and administrative expenses were $59.6 million, with notable increases due to ERP implementation costs and severance expenses, partially offset by lower compensation-related expenses.
• The company is working to resolve ongoing operational challenges related to its ERP system implementation, which launched in Q2 2026, and anticipates resolution in Q3 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing positively due to strong revenue growth and a return to profitability, despite ongoing integration challenges with a new ERP system.

Positives

• Net sales surged by 111.0% year-over-year to $93.5 million in Q2 2026.
• Gross profit margin improved to 74.5% from 74.0% in Q2 2025.
• The company returned to profitability with a net income of $8.1 million in Q2 2026, compared to a net loss of $16.8 million in Q2 2025.
• Strong sales performance in China was a key driver of revenue growth, with sales to China distributors increasing significantly.
• APAC region sales increased by 189% year-over-year.
• Americas region sales increased by 12% year-over-year.
• Cash and investments available for sale increased to $181.5 million at July 3, 2026.

Negatives

• Selling, general, and administrative expenses increased due to depreciation and consulting costs related to the ERP implementation.
• Severance expenses were incurred due to headcount reductions in Global Marketing.
• Ongoing operational challenges with the ERP system implementation required extensive manual intervention.
• Gross margin is expected to be impacted by tariffs until 100% of EVO and EVO+ ICL lenses for China can be supplied from Switzerland by the end of 2026.
• EMEA region sales decreased by 1% year-over-year, primarily due to the situation in the Middle East.

Risks

• Potential for continued operational challenges with the ERP system implementation.
• Impact of tariffs on gross margin until supply chain adjustments are fully implemented.
• Dependence on independent distributors in international markets.
• Global economic conditions and potential slowdowns or disruptions in key markets like China.
• Fluctuations in foreign currency exchange rates.
• International trade disputes and substantial dependence on demand from Asia.
• Competition in the ophthalmic surgical product market.
• Potential losses due to product liability claims or medical device quality compliance issues.

Future Outlook

The company expects to continue generating cash and anticipates resolving ERP implementation issues in the third quarter of 2026. Gross margins are expected to be impacted by tariffs until the full transition of China supply to Switzerland by the end of 2026. The company believes its current liquidity sources will be sufficient for at least the next 12 months.

Management Comments

• "As sales volumes grew, unforeseen operational challenges emerged that required extensive daily manual intervention from teams across the organization. Through these concentrated efforts, the Company successfully met its sales targets for the quarter."
• "While certain implementation-related issues persist, the Company has developed a comprehensive remediation plan and anticipates resolving these matters in the third quarter of 2026."
• "Gross margin will continue to be impacted by tariffs until we can supply 100% of EVO and EVO+ ICL lenses for China from Switzerland, which should happen by the end of 2026."

Industry Context

StockSavvy.ai notes that STAAR Surgical's strong performance, particularly in the APAC region and specifically China, aligns with broader trends of increasing adoption of advanced ophthalmic surgical solutions globally. The company's focus on ICLs positions it within a growing segment of the refractive surgery market.

Comparison to Industry Standards

• STAAR Surgical's gross profit margin of 74.5% is robust for the medical device industry, though direct comparisons are difficult without specific segment data from competitors like Alcon or Johnson & Johnson Vision.
• The company's revenue growth of 111.0% significantly outpaces typical growth rates for established medical device companies, indicating strong market penetration or expansion.
• The return to profitability from a substantial loss demonstrates effective cost management and sales execution, a key indicator of operational health within the sector.

Management Changes

Legal Proceedings

• The company is involved in various legal proceedings, claims, regulatory actions, and other matters arising in the normal course of business, including those related to contractual rights, vendor/distributor relations, employment, product liability, and medical device quality compliance. While no known claims are expected to have a material adverse effect, new claims or unexpected results could cause significant financial harm.

Related Party Transactions

• The Company paid $5,036,000 to Broadwood and $962,000 to Yunqi Capital in accordance with the Cooperation Agreement, which involved reimbursement of fees and expenses related to the terminated merger with Alcon. Broadwood and Yunqi Capital were holders of more than 5% of the Company's outstanding stock at the time.

Stakeholder Impact

• Shareholders: Positive impact from return to profitability and strong revenue growth, offset by ongoing ERP integration risks and tariff impacts.
• Employees: Potential impact from severance expenses related to headcount reductions in Global Marketing.
• Distributors: Continued reliance on distributors, with significant sales concentration in China.
• Creditors: No immediate concerns indicated regarding financial stability.

Next Steps

• Resolve ongoing operational challenges related to the ERP system implementation in Q3 2026.
• Continue efforts to supply 100% of EVO and EVO+ ICL lenses for China from Switzerland by the end of 2026 to mitigate tariff impacts.
• Continue to drive awareness and surgeon training for ICL procedures.
• Monitor and manage global economic conditions and geopolitical factors impacting sales.

Key Dates

Recommendation

The strong revenue growth and return to profitability are positive indicators. However, the ongoing ERP implementation challenges, potential tariff impacts, and significant sales concentration in China introduce notable risks that warrant a cautious 'hold' stance until these issues are resolved and the company demonstrates sustained, stable growth.

Keywords

STAAR Surgical, ICL, Implantable Collamer Lenses, Ophthalmic Surgery, Refractive Surgery, China Sales, ERP Implementation, Gross Margin